<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34274994</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1447</StartPage><EndPage>1455</EndPage><MedlinePgn>1447-1455</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10716-1</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Exploration of hypermetabolism in amyotrophic lateral sclerosis (ALS) with different ethnicities is needed to understand its metabolic implications for clinical management. We aimed to evaluate the features of hypermetabolism and investigate its association with clinical characteristics and prognosis of ALS in a prospective Chinese cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study was conducted at Peking University Third Hospital, China from 2017 to 2020. 343 participants were enrolled initially. After strict screening, 147 matched health controls and 93 patients with ALS were eligible and underwent detailed clinical assessments. Disease severity and progression were evaluated using recognized scales. Metabolic assessments included body composition and metabolic index (MI) [hypermetabolism if MI&#x2009;&#x2265;&#x2009;120.0%]. Patients were followed up every 6&#xa0;months for survival analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with controls, hypermetabolism was significantly more prevalent in ALS (p&#x2009;=&#x2009;0.009). MI was consistently higher in ALS than controls (p&#x2009;=&#x2009;0.009). Further correlation analysis showed that MI significantly decreased with disease progression, as graded by King's College staging system (p&#x2009;&lt;&#x2009;0.001). MI was significantly correlated with fat-free mass and fat mass (p&#x2009;=&#x2009;0.005 and 0.007). Survival analysis showed that hypermetabolism independently indicated a worse prognosis for ALS (HR&#x2009;=&#x2009;1.020, CI&#x2009;=&#x2009;1.004-1.036, p&#x2009;=&#x2009;0.013).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A significant increase in the prevalence and degree of hypermetabolism was identified in ALS compared with strictly matched controls. Metabolic index, which is significantly associated with disease progression and body composition, is an independent prognostic indicator for a worse survival of ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fu</LastName><ForeName>Jiayu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physical Examination Center, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physical Examination Center, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physical Examination Center, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physical Examination Center, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lequn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yixuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xinran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gaoqi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Dongsheng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3129-9821</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, Haidian District, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China. dsfan2010@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82001347</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81873484</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82071426</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81974197</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>BYSY2018032</GrantID><Agency>Peking University Third Hospital</Agency><Country/></Grant><Grant><GrantID>BYSYDL2019002</GrantID><Agency>Peking University Third Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="N">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Energy metabolism</Keyword><Keyword MajorTopicYN="N">Hypermetabolism</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>18</Day><Hour>21</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34274994</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10716-1</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10716-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390(10107):2084&#x2013;2098</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolano M, Provitera V, Manganelli F et al (2017) Non-motor involvement in amyotrophic lateral sclerosis: new insight from nerve and vessel analysis in skin biopsy. Neuropathol Appl Neurobiol 43(2):119&#x2013;132</Citation><ArticleIdList><ArticleId IdType="pubmed">27288647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang B, Chen R et al (2015) Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 86(10):1075&#x2013;1081</Citation><ArticleIdList><ArticleId IdType="pubmed">26124198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Sobue G, Kuwabara S et al (2016) Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry 87(8):821&#x2013;830</Citation><ArticleIdList><ArticleId IdType="pubmed">27093948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10(1):75&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Crugnola V, Lamperti C, Lucchini V et al (2010) Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol 67(7):849&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pubmed">20625092</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA et al (2018) Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89(10):1016&#x2013;1023</Citation><ArticleIdList><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L (2018) Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol 135(4):489&#x2013;509</Citation><ArticleIdList><ArticleId IdType="pubmed">29549424</ArticleId><ArticleId IdType="pmc">5978930</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L et al (2001) Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 74(3):328&#x2013;334</Citation><ArticleIdList><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Torny F, Lacoste M, Preux PM, Couratier P (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2(3&#x2013;4):202&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P et al (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256(8):1236&#x2013;1242</Citation><ArticleIdList><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AM, Hubbard J, Macklin EA et al (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383(9934):2065&#x2013;2072</Citation><ArticleIdList><ArticleId IdType="pubmed">24582471</ArticleId><ArticleId IdType="pmc">4176708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J et al (2020) Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 87(2):206&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand D, Polak M, Glass JD, Fournier CN (2021) Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic. Neurology 96(6):e840&#x2013;e844</Citation><ArticleIdList><ArticleId IdType="pubmed">33372030</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Fu JY, Chen L et al (2020) Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol. BMJ Open 10(12):e042603</Citation><ArticleIdList><ArticleId IdType="pubmed">33277290</ArticleId><ArticleId IdType="pmc">7722390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheung YK (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 67(7):1314&#x2013;1315</Citation><ArticleIdList><ArticleId IdType="pubmed">17030785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Cudkowicz ME, de Carvalho M et al (2018) Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 19(5&#x2013;6):321&#x2013;330</Citation><ArticleIdList><ArticleId IdType="pubmed">29566571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Paul P, Jorg C (2007) Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68(19):1571&#x2013;1575</Citation><ArticleIdList><ArticleId IdType="pubmed">17485643</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM et al (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3):847&#x2013;852</Citation><ArticleIdList><ArticleId IdType="pubmed">22271664</ArticleId><ArticleId IdType="pmc">3286327</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59&#x2013;e69</Citation><ArticleIdList><ArticleId IdType="pubmed">32385188</ArticleId><ArticleId IdType="pmc">7371380</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi K, Liu L, He YJ et al (2016) Body composition and bone mineral status in patients with Turner syndrome. Sci Rep 6:38026</Citation><ArticleIdList><ArticleId IdType="pubmed">27901060</ArticleId><ArticleId IdType="pmc">5128814</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WM, Spring TJ, Zalesin KC et al (2012) Lower than predicted resting metabolic rate is associated with severely impaired cardiorespiratory fitness in obese individuals. Obesity (Silver Spring) 20(3):505&#x2013;511</Citation></Reference><Reference><Citation>Weir JB (1949) New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109(1&#x2013;2):1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">15394301</ArticleId><ArticleId IdType="pmc">1392602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis AC, Rosenfeld J (2011) Which equation best predicts energy expenditure in amyotrophic lateral sclerosis? J Am Diet Assoc 111(11):1680&#x2013;1687</Citation><ArticleIdList><ArticleId IdType="pubmed">22027050</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus P, Fayemendy P, Nicol M et al (2018) Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol 25(1):97&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman MS, Pillai A, Jackson A, Heiman-Patterson T (2004) Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis. JPEN J Parenter Enteral Nutr 28(6):442&#x2013;446</Citation><ArticleIdList><ArticleId IdType="pubmed">15568293</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisman N, Lusaus M, Nefussy B et al (2009) Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci 279(1&#x2013;2):26&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">19185883</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B, Desport JC, Sturtz F, Camu W, Couratier P (2009) High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10(2):113&#x2013;117</Citation><ArticleIdList><ArticleId IdType="pubmed">18792852</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges M, Mor&#xe9;lot-Panzini C, Similowski T, Gonzalez-Bermejo J (2014) Noninvasive ventilation reduces energy expenditure in amyotrophic lateral sclerosis. BMC Pulm Med 14:17</Citation><ArticleIdList><ArticleId IdType="pubmed">24507664</ArticleId><ArticleId IdType="pmc">3922008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Ke YD, Vucic S et al (2018) Physiological changes in neurodegeneration - mechanistic insights and clinical utility. Nat Rev Neurol 14(5):259&#x2013;271</Citation><ArticleIdList><ArticleId IdType="pubmed">29569624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ (1996) Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 63(1):130&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pubmed">8604660</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Desport JC, Kajeu P et al (2011) Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 82(6):628&#x2013;634</Citation><ArticleIdList><ArticleId IdType="pubmed">21097551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, de Aguilar JLG, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 101(30):11159&#x2013;11164</Citation><ArticleIdList><ArticleId IdType="pubmed">15263088</ArticleId><ArticleId IdType="pmc">503756</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J, Blommaert J, Devrome M et al (2020) Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol 77(8):1008&#x2013;1017</Citation><ArticleIdList><ArticleId IdType="pubmed">32421156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ (2016) Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegener Dis 16(5&#x2013;6):382&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">27400276</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S, King A, Cleveland M et al (2014) Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol Commun 2:165</Citation><ArticleIdList><ArticleId IdType="pubmed">25510661</ArticleId><ArticleId IdType="pmc">4297389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon GS, Im W, Shim YM et al (2016) Neuroprotective effect of human adipose stem cell-derived extract in amyotrophic lateral sclerosis. Neurochem Res 41(4):913&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">26646002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247&#x2013;2257</Citation><ArticleIdList><ArticleId IdType="pubmed">4456658</ArticleId><ArticleId IdType="pmc">4456658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, Steyn FJ, Ngo ST, Borges K (2021) CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target? Cell Biosci 11(1):14</Citation><ArticleIdList><ArticleId IdType="pubmed">33431046</ArticleId><ArticleId IdType="pmc">7798275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MS, Cui LY, Fan DS (2014) Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand 129(3):163&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">23819875</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Chen L, Wang S et al (2020) Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry 91(5):520&#x2013;525</Citation><ArticleIdList><ArticleId IdType="pubmed">32139654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>